CollPlant Biotechnologies Ltd.
| NASDAQ: CLGN | Healthcare / Biotechnology / Israel |
| 5.83 | +0.0851 | +1.48% | Vol 8.07K | 1Y Perf -15.02% |
| Oct 4th, 2023 15:23 DELAYED |
| BID | 5.75 | ASK | 5.85 | ||
| Open | 5.75 | Previous Close | 5.74 | ||
| Pre-Market | - | After-Market | 5.69 | ||
| - - | -0.15 -2.49% |
| Target Price | 17.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 191.60 | Finscreener Ranking | ★★★★+ 56.21 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★+ 44.62 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★ 57.60 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 16.08 | Earnings Rating | Strong Buy | |
| Market Cap | 65.24M | Earnings Date | 24th Aug 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.21 | |
| Beta | 0.29 |
Today's Price Range 5.665.83 | 52W Range 4.2713.97 | 5 Year PE Ratio Range -300.90-3.90 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 2.59% | ||
| 1 Month | -16.38% | ||
| 3 Months | -27.55% | ||
| 6 Months | -22.16% | ||
| 1 Year | -15.02% | ||
| 3 Years | -27.55% | ||
| 5 Years | 14.67% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -41.72 | |||
ROE last 12 Months | -42.40 | |||
ROA (5Y Avg) | -6.27 | |||
ROA last 12 Months | -37.90 | |||
ROC (5Y Avg) | -85.07 | |||
ROC last 12 Months | -36.01 | |||
Return on invested Capital Q | -10.78 | |||
Return on invested Capital Y | -7.56 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 70.10 | ||||
| 3.43 | ||||
| 329.12 | ||||
| 15.50 | ||||
| -15.30 | ||||
| 1.13 | ||||
| 4.85 | ||||
| 5.11 | ||||
| 127.23M | ||||
| Forward PE | -13.92 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 14.30 | ||||
| 14.80 | ||||
| 0.06 | ||||
| 0.08 | ||||
| -1 873.30 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -60.80 | ||||
| -2 944.60 | ||||
| -2 762.10 | ||||
| -624.30 | ||||
| 1.16 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 241.00K | ||||
| 0.02 | ||||
| 23.45 | ||||
| 99.98 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.35 | 0.49 | 240.00 |
| Q01 2023 | -0.29 | -0.33 | -13.79 |
| Q04 2022 | -0.21 | -0.39 | -85.71 |
| Q03 2022 | -0.31 | -0.40 | -29.03 |
| Q02 2022 | -0.08 | -0.39 | -387.50 |
| Q01 2022 | -0.14 | -0.36 | -157.14 |
| Q04 2021 | -0.26 | -0.30 | -15.38 |
| Q03 2021 | -0.28 | -0.29 | -3.57 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.02 | 85.71 | Positive |
| 12/2023 QR | -0.42 | -800.00 | Negative |
| 12/2023 FY | 0.97 | 182.91 | Positive |
| 12/2024 FY | -0.40 | -66.67 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | -0.34 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 8.07K |
| Shares Outstanding | 11.19K |
| Shares Float | 8.80M |
| Trades Count | 62 |
| Dollar Volume | 46.48K |
| Avg. Volume | 13.57K |
| Avg. Weekly Volume | 10.73K |
| Avg. Monthly Volume | 14.34K |
| Avg. Quarterly Volume | 15.66K |
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) stock closed at 5.7449 per share at the end of the most recent trading day (a 0.61% change compared to the prior day closing price) with a volume of 1.72K shares and market capitalization of 65.24M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 38 people. CollPlant Biotechnologies Ltd. CEO is Yehiel Tal.
The one-year performance of CollPlant Biotechnologies Ltd. stock is -15.02%, while year-to-date (YTD) performance is -31.2%. CLGN stock has a five-year performance of 14.67%. Its 52-week range is between 4.27 and 13.97, which gives CLGN stock a 52-week price range ratio of 16.08%
CollPlant Biotechnologies Ltd. currently has a PE ratio of 70.10, a price-to-book (PB) ratio of 3.43, a price-to-sale (PS) ratio of 329.12, a price to cashflow ratio of 15.50, a PEG ratio of -, a ROA of -37.90%, a ROC of -36.01% and a ROE of -42.40%. The company’s profit margin is 1.16%, its EBITDA margin is -2 762.10%, and its revenue ttm is $241.00 Thousand , which makes it $0.02 revenue per share.
Of the last four earnings reports from CollPlant Biotechnologies Ltd., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. CollPlant Biotechnologies Ltd.’s next earnings report date is -.
The consensus rating of Wall Street analysts for CollPlant Biotechnologies Ltd. is Strong Buy (1), with a target price of $17, which is +191.60% compared to the current price. The earnings rating for CollPlant Biotechnologies Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CollPlant Biotechnologies Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CollPlant Biotechnologies Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 25.17, ATR14 : 0.37, CCI20 : -67.96, Chaikin Money Flow : -0.18, MACD : -0.32, Money Flow Index : 12.57, ROC : -16.13, RSI : 38.61, STOCH (14,3) : 19.59, STOCH RSI : 1.00, UO : 49.54, Williams %R : -80.41), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CollPlant Biotechnologies Ltd. in the last 12-months were:
CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd is a regenerative medicine company. It is focused on developing and commercializing tissue repair products, initially for 3D-bio printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets. Its products are based on recombinant human collagen produced from genetically-modified tobacco plants, and the company focuses on orthopedics and advanced wound care.
CEO: Yehiel Tal
Telephone: +972 732325600
Address: 4 Oppenheimer Street, Rehovot 7670104, , IL
Number of employees: 38
